Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
Siobhan Calafiore, Senior Journalist at the limbic, shared a post on LinkedIn about a recent article she authored, published in The Limbic:
“This week I reported on the landmark COBRRA trial addressing one of the common clinical dilemmas for haematologists treating community-acquired blood clots, ‘which anticoagulant do I give my patient?’
For years, clinical guidelines have been unable to preference one DOAC over the other due to a complete lack of head-to-head trials.
The latest findings suggest while both DOACs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, more than halving the risk of bleeding.
Australia had a big role to play in this practice-changing study and I was lucky enough to chat to Australia’s lead investigator Vivien Chen about the practical difference these findings will make in everyday practice around the world. ”
Title: Landmark VTE trial backs apixaban over rivaroxaban
Authors: Siobhan Calafiore
Read the Full Article on The Limbic
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 14:14From the Clinical Transfusion Working Party – 2025 International Platelet Transfusion Guidelines – ISBT
-
Apr 14, 2026, 13:48Antoine Francis: This Is What a Donation Actually Becomes.
-
Apr 14, 2026, 13:09Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
-
Apr 14, 2026, 13:01Shahzaib Maqbool: Preeclampsia Through a Hematology Lens
-
Apr 14, 2026, 12:46Rosa Hart: Inside Pediatric Stroke Recovery with Dr. Catherine Schuster
-
Apr 14, 2026, 12:39Gonzalo Ladreda: Innovation in Stroke Care Is About Timing, Integration, and Real-World Usability
-
Apr 14, 2026, 12:30Roy P.C. Kessels: Stroke’s Cognitive Impact on Young Adults Is Significant and Often Overlooked
-
Apr 14, 2026, 12:22Mehari Gebreyohanns: New Insights on Wake-Up Strokes from Emergency Settings in Texas and Louisiana
-
Apr 14, 2026, 12:08Enrico Ferro: Comparative Study Raises Questions on PFA Safety in AF at EHRA 2026